Literature DB >> 6199418

Biochemical and functional characterization of proteoglycans isolated from basophils of patients with chronic myelogenous leukemia.

D D Metcalfe, C E Bland, S I Wasserman.   

Abstract

Human basophils were obtained from three donors with myelogenous leukemia. Proteoglycans were labeled by using [35S]sulfate as precursor and were extracted in 1 M NaCl with protease inhibitors to preserve their native structure. [35S]proteoglycans filtered on Sepharose 4B with an average m.w. similar to that of a rat heparin proteoglycan that has an estimated m.w. of 750,000. The [35S]glycosaminoglycan side chains filtered with an average m.w. slightly smaller than a 60,000-m.w. glycosaminoglycan marker. The [35S]glycosaminoglycans were resistant to heparinase and susceptible to degradation by chondroitin AC lyase and chondroitin ABC lyase. The intact [35S]glycosaminoglycans chromatographed on DEAE Sepharose as a single peak eluting just before an internal heparin marker. These findings indicate that the [35S]glycosaminoglycans were made up only of chondroitin sulfates. No heparin was identified. The chondroitin sulfate disaccharides that resulted from the action of chondroitin ABC lyase on the basophil glycosaminoglycans consisted of 92% delta Di-4S, 6% delta Di-6S, and 2% disulfated disaccharides. The [35S]chondroitin sulfate proteoglycans were susceptible to cleavage with proteases and could be shown to be released intact from basophils during degranulation initiated by the calcium ionophore A23187. The basophil proteoglycans and glycosaminoglycans were capable of binding histamine in water, but not in phosphate-buffered saline, and had no anticoagulant activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199418

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Regulation of human mast cell tryptase. Effects of enzyme concentration, ionic strength and the structure and negative charge density of polysaccharides.

Authors:  S C Alter; D D Metcalfe; T R Bradford; L B Schwartz
Journal:  Biochem J       Date:  1987-12-15       Impact factor: 3.857

2.  Cultured human bone marrow-derived mast cells, their similarities to cultured murine E-mast cells.

Authors:  L Gilead; E Rahamim; I Ziv; R Or; E Razin
Journal:  Immunology       Date:  1988-04       Impact factor: 7.397

3.  Ultrastructure of proteoglycans in the specific granules of guinea-pig basophilic leukocytes as demonstrated by cuprolinic blue staining.

Authors:  G Landemore; M Quillec; J Izard
Journal:  Histochem Cell Biol       Date:  1995-03       Impact factor: 4.304

Review 4.  Mast cell heterogeneity: evidence and implications.

Authors:  K E Barrett; D D Metcalfe
Journal:  J Clin Immunol       Date:  1984-07       Impact factor: 8.317

5.  Chondroitin sulphate inhibits connective tissue mast cells.

Authors:  T C Theoharides; P Patra; W Boucher; R Letourneau; D Kempuraj; G Chiang; S Jeudy; L Hesse; A Athanasiou
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

6.  Two mutations within a feline mucopolysaccharidosis type VI colony cause three different clinical phenotypes.

Authors:  A C Crawley; G Yogalingam; V J Muller; J J Hopwood
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

7.  Proteoglycan synthesis in human erythroleukaemia (HEL) cells.

Authors:  B P Schick; S Senkowski-Richardson
Journal:  Biochem J       Date:  1992-03-15       Impact factor: 3.857

8.  Mast cell-derived particles deliver peripheral signals to remote lymph nodes.

Authors:  Christian A Kunder; Ashley L St John; Guojie Li; Kam W Leong; Brent Berwin; Herman F Staats; Soman N Abraham
Journal:  J Exp Med       Date:  2009-10-05       Impact factor: 14.307

9.  Expression and enhanced secretion of proteochondroitin sulphate in a metastatic variant of a mouse lymphoma cell line.

Authors:  R Schwartz-Albiez; I Steffen; A Lison; N Güttler; V Schirrmacher; R Keller
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.